Clinical first‑in‑human studies, upscaling and manufacture of Good Manufacturing Practice material of the complement component C5a inhibitor AON‑D21 for demonstration of efficacy in COVID‑19 patients

✏️ Listing Description:

📁 Related Knowledgebase Resources

.

📁 Related Innovation Offers

.

📁 Related Funding and Finance Opportunities

.

Access Restricted

This knowledgebase resource is only fully available for users with Personal Access or Professional Access.

Already member? - Login Get instant access (19,99 € / month) See your options Book a Meeting